Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Revenue (2016 - 2025)

IGC Pharma (IGC) has disclosed Revenue for 16 consecutive years, with $191000.0 as the latest value for Q3 2025.

  • Quarterly Revenue fell 53.64% to $191000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Sep 2025, down 6.51% year-over-year, with the annual reading at $1.3 million for FY2025, 5.5% down from the prior year.
  • Revenue for Q3 2025 was $191000.0 at IGC Pharma, down from $328000.0 in the prior quarter.
  • The five-year high for Revenue was $555000.0 in Q2 2023, with the low at $56000.0 in Q3 2021.
  • Average Revenue over 5 years is $238157.9, with a median of $212000.0 recorded in 2022.
  • The sharpest move saw Revenue plummeted 86.82% in 2021, then skyrocketed 260.71% in 2022.
  • Over 5 years, Revenue stood at $142000.0 in 2021, then skyrocketed by 133.8% to $332000.0 in 2022, then tumbled by 38.55% to $204000.0 in 2023, then grew by 25.98% to $257000.0 in 2024, then decreased by 25.68% to $191000.0 in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $191000.0, $328000.0, and $330000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.